Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | SCD | O00767 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20458131 | 0.88 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL13058942 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| Acetic Acid SCHEMBL7433376 | 0.85 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL11380131 | 0.85 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL2658434 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL31430548 | 0.84 | HDAC6 (0.62) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL31430584 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL13002091 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL22703575 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL3453070 | 0.83 | ELANE (0.76) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| US-4275210-A | IMMUNOSUPPRESSIVE AGENTS, ANTIFERTILITY AGENTS, PROPHYLAXIS OF MAREK'S DISEASE IN CHICKENS AND HERBICIDES | ELI LILLY AND COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
| US-4088770-A | ANTIFERTILITY, HERBICIDES | ELI LILLY AND COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | NPC1 3565/4885RAB9A 1592/4885SMN1; SMN2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.